Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)

Ähnliche Einträge

• Mission impossible? Caveats in interpreting and comparing long‐term efficacy in biologic studies for moderate‐to‐severe plaque psoriasis
  von: Richard G. Langley, et al.
  Veröffentlicht: (2025)
• Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data
  von: Charlotte M. Thomas, et al.
  Veröffentlicht: (2026)
• A novel nomogram to predict psoriatic arthritis in patients with plaque psoriasis
  von: Minjia Tan, et al.
  Veröffentlicht: (2024)
• Real‐world effectiveness, drug survival and safety of risankizumab over a period of 2 years in 158 patients with moderate‐to‐severe plaque psoriasis
  von: Natalia Rompoti, et al.
  Veröffentlicht: (2024)
• Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study
  von: A. Bagit, et al.
  Veröffentlicht: (2024)